[go: up one dir, main page]

FR18C1047I2 - INTRACELLULAR VECTOR FORMULATIONS FOR ANTHRACYCLINICS AND CYTIDINE ANALOGUES - Google Patents

INTRACELLULAR VECTOR FORMULATIONS FOR ANTHRACYCLINICS AND CYTIDINE ANALOGUES

Info

Publication number
FR18C1047I2
FR18C1047I2 FR18C1047C FR18C1047C FR18C1047I2 FR 18C1047 I2 FR18C1047 I2 FR 18C1047I2 FR 18C1047 C FR18C1047 C FR 18C1047C FR 18C1047 C FR18C1047 C FR 18C1047C FR 18C1047 I2 FR18C1047 I2 FR 18C1047I2
Authority
FR
France
Prior art keywords
anthracyclinics
vector formulations
cytidine analogues
intracellular vector
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1047C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Therapeutics Inc
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of FR18C1047I1 publication Critical patent/FR18C1047I1/en
Application granted granted Critical
Publication of FR18C1047I2 publication Critical patent/FR18C1047I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
FR18C1047C 2004-04-22 2018-11-14 INTRACELLULAR VECTOR FORMULATIONS FOR ANTHRACYCLINICS AND CYTIDINE ANALOGUES Active FR18C1047I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56521004P 2004-04-22 2004-04-22
PCT/CA2005/000625 WO2005102359A1 (en) 2004-04-22 2005-04-22 Liposomal formulations of anthracycline agents and cytidine analogs

Publications (2)

Publication Number Publication Date
FR18C1047I1 FR18C1047I1 (en) 2019-03-22
FR18C1047I2 true FR18C1047I2 (en) 2019-10-04

Family

ID=35196733

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1047C Active FR18C1047I2 (en) 2004-04-22 2018-11-14 INTRACELLULAR VECTOR FORMULATIONS FOR ANTHRACYCLINICS AND CYTIDINE ANALOGUES

Country Status (13)

Country Link
US (2) US8022279B2 (en)
EP (2) EP1744764B1 (en)
JP (1) JP4972545B2 (en)
AU (1) AU2005235455B2 (en)
BE (1) BE2018C045I2 (en)
CA (1) CA2564542C (en)
CY (2) CY1113012T1 (en)
ES (1) ES2388064T3 (en)
FR (1) FR18C1047I2 (en)
IL (1) IL178779A (en)
NL (1) NL300960I2 (en)
PT (1) PT1744764E (en)
WO (1) WO2005102359A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032136A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Branch Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
EP1888034A2 (en) * 2005-05-26 2008-02-20 Yissum Research Development Company, of The Hebrew University of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
ES2909903T3 (en) * 2007-02-16 2022-05-10 Rotalec Ip Holdings Llc Fixed ratios of drugs for the treatment of hematopoietic cancer and proliferative disorders
WO2009106549A2 (en) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
CN101912363A (en) * 2010-07-29 2010-12-15 蔡海德 Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine
KR102284689B1 (en) 2011-10-21 2021-08-02 셀라토 파마슈티칼즈, 인코포레이티드 Lyophilized liposomes
KR101626703B1 (en) 2012-04-04 2016-06-02 할로자임, 아이엔씨 Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
SG10201914117QA (en) * 2012-05-09 2020-02-27 Cantex Pharmaceuticals Inc Treatment Of Myelosuppression
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
RU2717824C2 (en) 2015-05-04 2020-03-26 Ферзантис Аг METHOD OF PRODUCING VESICLES WITH TRANSMEMBRANE GRADIENT pH
JP6564873B2 (en) * 2015-11-02 2019-08-21 富士フイルム株式会社 Liposome composition and production method thereof
CN108778260A (en) 2015-11-11 2018-11-09 塞拉特药物股份有限公司 Analysis and method for selecting treatment regimens for leukemia subjects
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US20240252522A1 (en) 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
CN113473980A (en) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 Gamma-hydroxybutyrate compositions with improved pharmacokinetics in fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
KR20230131934A (en) * 2021-01-20 2023-09-14 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Combination therapy schedule to treat cancer
CN113181117B (en) * 2021-03-22 2022-08-26 沈阳药科大学 Shikonin and anthracycline chemotherapeutic drug co-carried liposome and preparation method and application thereof
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (en) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
MX9203808A (en) 1987-03-05 1992-07-01 Liposome Co Inc HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS.
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2186484B1 (en) 2000-10-10 2004-07-01 Lipotec, S.A. LIPOSOMES ENCAPSULATING ANTI-CANCER DRUGS AND USE OF THEM IN THE TREATMENT OF EVIL TUMORS.
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
DE60237162D1 (en) * 2001-10-03 2010-09-09 Celator Pharmaceuticals Inc LIPOSOMENIC LOADING WITH METALLIONS
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20060240090A1 (en) 2003-04-02 2006-10-26 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents

Also Published As

Publication number Publication date
BE2018C045I2 (en) 2024-08-08
CA2564542A1 (en) 2005-11-03
IL178779A0 (en) 2007-05-15
US20070286897A1 (en) 2007-12-13
WO2005102359A8 (en) 2005-12-15
EP1744764A1 (en) 2007-01-24
CA2564542C (en) 2012-11-27
US20120009252A1 (en) 2012-01-12
EP1744764B1 (en) 2012-05-30
CY2018033I2 (en) 2019-07-10
ES2388064T3 (en) 2012-10-08
FR18C1047I1 (en) 2019-03-22
EP1744764A4 (en) 2009-04-01
PT1744764E (en) 2012-08-30
CY1113012T1 (en) 2016-04-13
HK1097194A1 (en) 2007-06-22
NL300960I2 (en) 2019-05-22
US8431806B2 (en) 2013-04-30
JP4972545B2 (en) 2012-07-11
IL178779A (en) 2013-12-31
EP2407169A1 (en) 2012-01-18
CY2018033I1 (en) 2019-07-10
WO2005102359A1 (en) 2005-11-03
JP2007533670A (en) 2007-11-22
AU2005235455B2 (en) 2011-01-20
US8022279B2 (en) 2011-09-20
AU2005235455A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
FR18C1047I2 (en) INTRACELLULAR VECTOR FORMULATIONS FOR ANTHRACYCLINICS AND CYTIDINE ANALOGUES
FIC20240007I1 (en) Gefapixant or a pharmaceutically acceptable salt thereof
IL181265A0 (en) Stabilizing formulations
DK1812025T3 (en) STABILIZED BACTERIOPHAGIC FORMULATIONS
DE602005015466D1 (en) ANTIVIRAL 4'-AZIDONUCLEOSIDE
DK1819670T3 (en) 12-aryl-prostaglandin analogues
MA29014B1 (en) ANTIBODY FORMULATIONS
DE50306910D1 (en) THREE-DIMENSIONAL KNOT STRUCTURE
GB0418172D0 (en) Vector
IS7861A (en) Marine lipid formulations
IL178596A0 (en) Sustained release formulations
DE60327330D1 (en) casting nozzle
GB0427001D0 (en) Vector
ZA200704086B (en) Antiinfective lipopeptides
IL183109A0 (en) Antiinfective lipopeptides
DE502004005390D1 (en) DELAY LOOP
EP1728504A4 (en) EMULSION STABILIZER
NO20045424D0 (en) ingredient container
EP1756276A4 (en) CRUSTACE EXPRESSION VECTOR
PL378439A1 (en) Depigmenting agents
FR2866666B1 (en) ABOUT SCAFFOLDING
FR2855509B1 (en) ERGONOMIC VENTRAL STRAP FOR EQUIDA
MA28462B1 (en) FORMULATIONS FOR INHALATION
UA11612S (en) PACKAGING FOR DUMPLINGS "MALYUK"
ITMN20040010A1 (en) PORTAMENU '